Folia Medica (Dec 2019)

Evaluation of Anti-HBs Antibody Immune Response against Hepatitis B virus in Vaccinated People in а North-eastern Bulgaria Region

  • Denitsa T. Tsaneva-Damyanova,
  • Liliya I. Ivanova,
  • Silviya N. Pavlova,
  • Svetlana B. Todorova,
  • Tsvetelina K. Popova

DOI
https://doi.org/10.3897/folmed.61.e47760
Journal volume & issue
Vol. 61, no. 4
pp. 572 – 578

Abstract

Read online Read online Read online

Introduction: Hepatitis B virus (HBV) is one of the most significant human pathogens responsible for a huge number of acute and chronic liver infectious diseases worldwide.Aim: To find the duration of post-vaccination immune response in individuals allocated to five age groups from 6 months to 20 years.Materials and methods: All tested subjects were born between 1999 and 2018 and therefore covered by the compulsory vaccination program against hepatitis B. For the serological marker anti-HBs Ab we investigated 449 serum samples taken from ambulatory people and patients of St Marina University Hospital in Varna.Results: A positive antibody response (anti-HBs Ab > 10 mIU/ml) was reported in 79.7% (n = 51) of the group of subjects up to one year old, in 70.0% (n = 196) of the subjects in the age range 1 year/1 month to 15 years, and in 39.3% (n = 33) of the subjects 15 years/1 month to 20 years old. Female sex had a better post-vaccination response than male sex with statistically significant relationship between sex and anti-HBs Ab titer (χ2 = 24.76, p <0.01).Conclusions: Regardless of the mass immunization against HBV in Bulgaria, the relative share of chronic HBV infections does not show a downward trend. Therefore, it is very important to study the duration of the post-vaccination immune response by demonstrating the anti-HBs antibodies and to apply a booster dose from the vaccine if needed.

Keywords